FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892344493> ?p ?o ?g. }

• W2892344493 endingPage "e14048" @default.
• W2892344493 startingPage "e14048" @default.
• W2892344493 abstract "e14048 Background: DNA-PK, with its protein subunits, Ku70 and Ku80, regulates one of the major pathways responsible for repair of double-strand breaks in DNA that are induced by radiotherapy (RT) and some chemotherapeutic agents (CT). Therefore, the combined strategy of RT with a DNA-PKi is promising. The purpose of this phase I trial is to explore the safety, tolerability, pharmacokinetic (PK) profile, and clinical activity of M3814 administered together with RT and chemo-RT (CRT). Methods: Patients (pts) with tumors or metastasis in the head and neck region or thorax in need of palliative RT (10 x 3 Gy) are eligible for the dose escalation part Ia, with a starting dose of 100 mg once daily. Dose escalation decisions are aided by the Bayesian logistic regression model with overdose control. Dose-limiting toxicity (DLT) is evaluated up to 3 weeks after RT. Rich PK sampling is taken during treatment. Tumor evaluation is performed every 6 weeks up to 6 months and every third month thereafter. Results: As of January 2017, 7 pts had been enrolled into the part Ia dose escalation arm and treated with 100 mg daily. The most frequent adverse events (AEs) were fatigue, constipation, decreased appetite, dry mouth, dysphagia, headache, oral pain, radiation skin injury, and mucositis in more than 1 pt (20%). No pts discontinued due to AE. Two episodes of grade 3 mucositis lasting > 7 days were reported; one of these was classified as a DLT, and both pts recovered without sequelae. Two of 7 pts enrolled had local tumor control at +300 days. PK analysis demonstrated high exposure variability. Conclusions: M3814 at the 100 mg daily dose was tolerable as palliative treatment and dose escalation is currently at 200 mg. In part Ib of the study, two separate dose escalation arms will enroll pts with either head and neck squamous cell carcinoma (SCCHN; US only) or non-small cell lung cancer (EU and US) to receive CRT 2 Gy x 30-35 over 6-7 weeks with curative intent; the SCCHN cohort is now open for enrollment. For these two cohorts, the DLT window will be 12 weeks. Clinical trial information: NCT02516813." @default.
• W2892344493 created "2018-09-27" @default.
• W2892344493 creator A5000212888 @default.
• W2892344493 creator A5010863018 @default.
• W2892344493 creator A5013406556 @default.
• W2892344493 creator A5028952075 @default.
• W2892344493 creator A5029444442 @default.
• W2892344493 creator A5030471739 @default.
• W2892344493 creator A5040484056 @default.
• W2892344493 creator A5054577726 @default.
• W2892344493 date "2017-05-20" @default.
• W2892344493 modified "2023-10-04" @default.
• W2892344493 title "A phase Ia/Ib trial of the DNA-dependent protein kinase inhibitor (DNA-PKi) M3814 in combination with radiotherapy in patients with advanced solid tumors." @default.
• W2892344493 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14048" @default.
• W2892344493 hasPublicationYear "2017" @default.
• W2892344493 type Work @default.
• W2892344493 sameAs 2892344493 @default.
• W2892344493 citedByCount "5" @default.
• W2892344493 countsByYear W28923444932017 @default.
• W2892344493 countsByYear W28923444932018 @default.
• W2892344493 countsByYear W28923444932020 @default.
• W2892344493 countsByYear W28923444932021 @default.
• W2892344493 crossrefType "journal-article" @default.
• W2892344493 hasAuthorship W2892344493A5000212888 @default.
• W2892344493 hasAuthorship W2892344493A5010863018 @default.
• W2892344493 hasAuthorship W2892344493A5013406556 @default.
• W2892344493 hasAuthorship W2892344493A5028952075 @default.
• W2892344493 hasAuthorship W2892344493A5029444442 @default.
• W2892344493 hasAuthorship W2892344493A5030471739 @default.
• W2892344493 hasAuthorship W2892344493A5040484056 @default.
• W2892344493 hasAuthorship W2892344493A5054577726 @default.
• W2892344493 hasConcept C112705442 @default.
• W2892344493 hasConcept C126322002 @default.
• W2892344493 hasConcept C141071460 @default.
• W2892344493 hasConcept C143998085 @default.
• W2892344493 hasConcept C197934379 @default.
• W2892344493 hasConcept C2778375690 @default.
• W2892344493 hasConcept C2778496288 @default.
• W2892344493 hasConcept C2780580376 @default.
• W2892344493 hasConcept C509974204 @default.
• W2892344493 hasConcept C71924100 @default.
• W2892344493 hasConcept C90924648 @default.
• W2892344493 hasConceptScore W2892344493C112705442 @default.
• W2892344493 hasConceptScore W2892344493C126322002 @default.
• W2892344493 hasConceptScore W2892344493C141071460 @default.
• W2892344493 hasConceptScore W2892344493C143998085 @default.
• W2892344493 hasConceptScore W2892344493C197934379 @default.
• W2892344493 hasConceptScore W2892344493C2778375690 @default.
• W2892344493 hasConceptScore W2892344493C2778496288 @default.
• W2892344493 hasConceptScore W2892344493C2780580376 @default.
• W2892344493 hasConceptScore W2892344493C509974204 @default.
• W2892344493 hasConceptScore W2892344493C71924100 @default.
• W2892344493 hasConceptScore W2892344493C90924648 @default.
• W2892344493 hasIssue "15_suppl" @default.
• W2892344493 hasLocation W28923444931 @default.
• W2892344493 hasOpenAccess W2892344493 @default.
• W2892344493 hasPrimaryLocation W28923444931 @default.
• W2892344493 hasRelatedWork W1973342136 @default.
• W2892344493 hasRelatedWork W2002502340 @default.
• W2892344493 hasRelatedWork W2022556905 @default.
• W2892344493 hasRelatedWork W2074207917 @default.
• W2892344493 hasRelatedWork W2394317912 @default.
• W2892344493 hasRelatedWork W2896565415 @default.
• W2892344493 hasRelatedWork W4205587618 @default.
• W2892344493 hasRelatedWork W4251165208 @default.
• W2892344493 hasRelatedWork W4296087748 @default.
• W2892344493 hasRelatedWork W4366822339 @default.
• W2892344493 hasVolume "35" @default.
• W2892344493 isParatext "false" @default.
• W2892344493 isRetracted "false" @default.
• W2892344493 magId "2892344493" @default.
• W2892344493 workType "article" @default.